Metastatic Urethral Urothelial Carcinoma Withdrawn Phase 2 Trials for Cyclophosphamide (DB00531)

Indication	Status	Phase
DBCOND0110111 (Metastatic Urethral Urothelial Carcinoma)	Withdrawn	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03935347	Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy	Treatment	Aldesleukin (DB00041) Cyclophosphamide (DB00531) Fludarabine (DB01073) Pembrolizumab (DB09037)